Skip to main content

Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “Charity is a supreme virtue, and the great channel through which the mercy of God is passed on to mankind. It is the virtue that unites men and inspires their noblest efforts.”

    — Conrad Hilton

Brain Tumor Research News

McGill University researchers identify proteins that drive cancer stem cells. Targeting and supressing a particular protein called galectin1 could provide a more effective treatment for glioblastoma, in combination with radiation therapy.

Stereotactic radiosurgery (SRS) is a well-established procedure for the non-invasive treatment of many primary and metastatic brain tumors, as well cranial functional and vascular disorders such as trigeminal neuralgia and arteriovenous malformations. Often considered an alternative to costly and invasive surgical procedures, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet requires no surgical incision, and little to no patient recovery period.

“We are actually treating and have been treating stereotactic brain cancer in Saskatoon since 2016,” Belitski said. “It’s a highly precise, highly conformal treatment, so it does require a lot of planning and treatment delivery. This tool helps increase the efficiency of the planning and treatment delivery, and allows that treatment to be done quicker.”

Dr. Anton Yuryev, Professional Services Director, Elsevier, explores the increasing importance of artificial intelligence (AI) within drug discovery and precision medicine and how it is helping to discover new treatments for children with aggressive brain tumours.

A team of researchers at Texas A&M University, Northwestern University, and ImmunoGenesis has discovered a treatment for glioblastoma that has promising implications for the human version of the aggressive cancer form that grows in the brain.

GammaTile is an implantable radiation therapy consisting of bioresorbable collagen tiles embedded with Cesium-131 sources provided by Isoray, Inc. It is the first medical device cleared for brain tumor treatment in the U.S. in the last ten years. "GammaTile Therapy improves the lives of patients with newly diagnosed malignant and recurrent brain tumors," said Matthew Likens, president and CEO of GT Medical Technologies, Inc.

View Previous News Articles - Click Here!